{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:48:16Z","timestamp":1776926896147,"version":"3.51.2"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1053\/j.seminhematol.2003.09.010","type":"journal-article","created":{"date-parts":[[2004,3,25]],"date-time":"2004-03-25T14:35:12Z","timestamp":1080225312000},"page":"23-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"S4","title":["The role of immunomodulatory drugs in multiple myeloma"],"prefix":"10.1053","volume":"40","author":[{"given":"Kenneth C","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2003.09.010_BIB1","series-title":"Cancer Facts and Figures 2003","year":"2003"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11864-002-0013-4","article-title":"Newly diagnosed multiple myeloma","volume":"3","author":"Weber","year":"2002","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB3","series-title":"Multiple myeloma. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology","author":"Anderson","year":"2002"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB4","series-title":"Cancer Principles and Practice of Oncology","first-page":"2465","article-title":"Plasma cell neoplasms","author":"Munshi","year":"2001"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4065\/77.8.813","article-title":"Current therapy for multiple myeloma","volume":"77","author":"Rajkumar","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB7","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB9","unstructured":"Richardson P, Jagannath S, Schlossman R, et al: Thalidomide for relapsed multiple myeloma after high dose therapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of efficacy, toxicity, and correlation with biological activity. (submitted)"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4065\/78.1.34","article-title":"Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma","volume":"78","author":"Kumar","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2003.09.010_BIB11","first-page":"211a","article-title":"Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma","volume":"100","author":"Palumbo","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB12","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1093\/annonc\/mdf258","article-title":"The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma","volume":"13","author":"Grover","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1582-4934.2002.tb00184.x","article-title":"Thalidomide as an anti-cancer agent","volume":"6","author":"Kumar","year":"2002","journal-title":"J Cell Mol Med"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/pmj.79.929.127","article-title":"Thalidomide and its derivatives","volume":"79","author":"Gordon","year":"2003","journal-title":"Postgrad Med J"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB15","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/jm9603328","article-title":"Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity","volume":"39","author":"Muller","year":"1996","journal-title":"J Med Chem"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB17","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB18","series-title":"Role of immunomodulatory drugs in multiple myeloma. Presented at the IXth International Myeloma Workshop, Salamanca, Spain, May 23\u201327","author":"Anderson","year":"2003"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB19","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/jpet.102.048496","article-title":"Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs","volume":"305","author":"Schafer","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2003.09.010_BIB20","first-page":"815a","article-title":"Mechanisms whereby immunomodulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity","volume":"100","author":"Hayashi","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB21","series-title":"Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway. Blood, prepublished Sept 25","author":"LeBlanc","year":"2003"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB22","doi-asserted-by":"crossref","first-page":"24453","DOI":"10.1074\/jbc.C100074200","article-title":"Apaf-1\/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells","volume":"276","author":"Chauhan","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB23","doi-asserted-by":"crossref","first-page":"17593","DOI":"10.1074\/jbc.C300076200","article-title":"JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells","volume":"278","author":"Chauhan","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2402745","article-title":"Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo","volume":"17","author":"Lentzsch","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB25","first-page":"775a","article-title":"Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT)","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB26","first-page":"104a","article-title":"A multi-center, randomized, phase II study to evaluate the efficacy and safety of two CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM)","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB27","series-title":"FDA grants fast track status for multiple myeloma therapy Revimid (CC-5013). Doctor\u2019s Guide","year":"2003"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB28","first-page":"314b","article-title":"Rituximab induced antibody dependent cell mediated cytotoxicity (ADCC) is enhanced by thalidomide and its analogue Revimid","volume":"100","author":"Hayashi","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2003.09.010_BIB29","unstructured":"Available at: http:\/\/www.clinicaltrials.gov. Accessed June 25, 2003"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196303002257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196303002257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:11:25Z","timestamp":1758521485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196303002257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":29,"alternative-id":["S0037196303002257"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2003.09.010","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2003,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of immunomodulatory drugs in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2003.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}